Physician profile
Michael K Rowe
NPI 1649298779
$2,945.79
in general payments reported to CMS, 2019-2025
33 companies · $752 in 2025
The $752 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $230 · 2021: $445 · 2022: $309 · 2023: $329 · 2024: $258 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.15 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Otsuka America Pharmaceutical, INC. | $281.26 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $229.44 | 2024-2025 | Auvelity |
| Grifols USA, LLC | $208.70 | 2019-2025 | Prolastin-C Liquid |
| Pfizer INC. | $193.32 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $164.02 | 2021 | |
| Astellas Pharma US INC | $159.58 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $146.37 | 2019-2023 | Livalo, Seglentis |
| Novo Nordisk INC | $126.62 | 2019-2024 | Wegovy |
| Amgen INC. | $122.62 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $86.67 | 2019-2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $75.93 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.44 | 2021-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $69.52 | 2019-2022 | |
| Allergan, INC. | $67.01 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $61.79 | 2020-2025 | Farxiga, Breztri |
| Daiichi Sankyo INC. | $61.69 | 2024 | Injectafer |
| Verona Pharma, INC. | $43.99 | 2025 | Ohtuvayre |
| Optinose US, INC. | $43.63 | 2025 | |
| Novartis Pharmaceuticals Corporation | $39.92 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $38.42 | 2023 | Gvoke Hypopen |
| Lilly USA, LLC | $37.04 | 2019-2022 | |
| Esperion Therapeutics, INC. | $32.33 | 2021-2022 | |
| Corcept Therapeutics | $31.13 | 2021-2023 | Korlym |
| Merck Sharp & Dohme LLC | $23.41 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $17.06 | 2022 | |
| Lundbeck LLC | $16.77 | 2024 | Rexulti |
| Amarin Pharma, INC. | $16.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.79 | 2025 | Voquezna |
| Mylan Specialty L.P. | $15.06 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.42 | 2020 | |
| Livanova USA, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.